Pre-market hot trades in US stocks: YY pre-market down nearly 12%, affected by a mix of technological innovation and cautious market sentiment

Popular Pre-Market Trades in US Stocks YY is down 11.99% in pre-market trading. Based on recent key news: On May 20, YY Group launched OpenClaw Agentic AI, aimed at enhancing hotel customer and internal operational efficiency. This move is seen as a technological innovation that could positively impact the company's future growth, but the market reacted poorly in the short term, leading to a drop in stock price. On May 18, YY Group announced the expansion of its business in Malaysia to Malacca, entering a new high-growth hotel market. Although this move shows the company's enthusiasm for expansion strategy, the market remains cautious about its short-term profitability, affecting stock performance. On May 18, YY Group issued a statement emphasizing that it does not assume responsibility for updating information, which may raise investor concerns about the company's transparency, further impacting stock price. The acceleration of technological innovation in the hotel industry has led to significant market volatility. Top Gainers in Pre-Market Trading in US Stocks Agape ATP is up 68.90% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Liminatus Pharma is up 59.16% in pre-market trading. Based on recent news: On May 21, Liminatus Pharma announced significant progress in new drug development. This news triggered a strong market reaction, driving the stock price sharply higher. On May 21, the company's CEO Chris Kim stated at a press conference that the company would further increase R&D investment to enhance market competitiveness. This positive outlook has boosted investor confidence, leading to continued stock price increases. On May 21, Liminatus Pharma mentioned in a press release via GlobeNewswire that the company is engaged in a significant strategic partnership, expected to significantly enhance the company's future profitability. This news further stimulated the stock price increase. The market reacted positively to the progress in new drug development, with noticeable fund inflows. Sunshine Biopharma is up 50.59% in pre-market trading. Based on recent key news: On May 18, Sunshine Biopharma's stock price surged 561.74% in pre-market trading, following a 39.46% drop the previous day. This extreme volatility is related to multiple reverse stock splits in the company's history, raising investor concerns about its stability. Source: Benzinga On May 19, Sunshine Biopharma announced the completion of a public offering of up to $18 million, with plans to use the proceeds for general corporate purposes and working capital. This news had a positive impact on the stock price. Source: Benzinga On May 21, Sunshine Biopharma received approval from Canadian regulators for its generic amoxicillin, with plans to start shipping to pharmacies in August 2026 This progress helps to expand its market share in the antibiotic market in Canada. Source: Public Technologies The pharmaceutical industry's innovative drug research and development is active, and market competition is fierce